Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination

References

• EzzatiMLopezADRodgersAVander HoornSMurrayCJSelected major risk factors and global and regional burden of diseaseLancet20023601347136012423980
   PubMed Web of Science ®Google Scholar
• Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trialsLancet20003561955196411130523
   PubMed Web of Science ®Google Scholar
• AgodoaLYEffect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trialJAMA20012852719272811386927
   PubMed Web of Science ®Google Scholar
• ChobanianAVThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA20032892560257212748199
   PubMed Web of Science ®Google Scholar
• ManciaGGuidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Eur Heart J2007281462153617562668
   PubMed Web of Science ®Google Scholar
• WeirMRTargeting mechanisms of hypertensive vascular disease with dual calcium channel and renin–angiotensin system blockadeJ Hum Hypertens20072177077917597800
   PubMed Web of Science ®Google Scholar
• WrightJTJrOutcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinoprilJAMA20052931595160815811979
   PubMed Web of Science ®Google Scholar
• DahlöfBCardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995101011937178
   PubMed Web of Science ®Google Scholar
• JamersonKBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med20083592417242819052124
   PubMed Web of Science ®Google Scholar
• Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension*J Hypertens200321
   Google Scholar
• ShimaECalcium channel blockers suppress cytokine-induced activation of human neutrophilsAm J Hypertens217884 (0 AD)18091748
   PubMed Web of Science ®Google Scholar
• ChrysantSGChrysantGSThe pleiotropic effects of angiotensin receptor blockersJ Clin Hypertens (Greenwich)2006826126816596029
   PubMed Web of Science ®Google Scholar
• KhalilSAElzubierAGDrug compliance among hypertensive patients in Tabuk, Saudi ArabiaJ Hypertens1997155615659170010
   PubMed Web of Science ®Google Scholar
• BangaloreSShahaneAParkarSMesserliFHCompliance and fixed-dose combination therapyCurr Hypertens Rep2007918418917519122
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: A meta-analysisAm J Med200712071371917679131
   PubMed Web of Science ®Google Scholar
• LeenenFHPatterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoringCan J Cardiol1997139149209374947
   PubMed Web of Science ®Google Scholar
• WanovichRKerrishPGerbinoPPShoheiberOP-518: Compliance patterns of patients treated with 2 separate antihypertensive agents versus fixed-dose combination therapyAm J Hypertens200417223 A15001195
   PubMed Web of Science ®Google Scholar
• LaffelLMMcGillJBGansDJThe beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study GroupAm J Med1995994975047485207
   PubMed Web of Science ®Google Scholar
• BrennerBMEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med200134586186911565518
   PubMed Web of Science ®Google Scholar
• LewisEJRenoprotective effect of the angiotensin–receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med200134585186011565517
   PubMed Web of Science ®Google Scholar
• MasonRPWalterMFTrumboreMWOlmsteadEGJrMasonPEMembrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipineJ Mol Cell Cardiol19993127528110072734
   PubMed Web of Science ®Google Scholar
• MasonRPCampbellSFWangSDHerbetteLGComparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranesMol Pharmacol1989366346402554114
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin–converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA20022882981299712479763
   PubMed Web of Science ®Google Scholar
• JuliusSOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialThe Lancet200436320222031
   PubMed Web of Science ®Google Scholar
• JuliusSThe Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving MonotherapyHypertens200648385391
   PubMed Web of Science ®Google Scholar
• PackerMEffect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart FailureN Engl J Med1996335110711148813041
   PubMed Web of Science ®Google Scholar
• DahlofBPrevention of cardiovascular events with an anti-hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet200536689590616154016
   PubMed Web of Science ®Google Scholar
• VolpeMBrommerPHaagUMieleCEfficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig2009291125
   PubMed Web of Science ®Google Scholar
• BarriosVBrommerPHaagUCalderonAEscobarCOlmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig200929427439
   PubMed Web of Science ®Google Scholar
• ChrysantSGMelinoMKarkiSLeeJHeyrmanRThe combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety studyClin Ther20083058760418498909
   PubMed Web of Science ®Google Scholar
• OparilSLong-term efficacy of a combination of amlodipine and olmesartan medoxomil +/−hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trialJ Hum Hypertens2010
   Web of Science ®Google Scholar
• VolpeMMieleCHaagUEfficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term studyClin Drug Investig200929381391
   PubMed Web of Science ®Google Scholar
• FutaiRItoTKawanishiYTerasakiFKitauraYOlmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertensionHeart Vessels20092429430019626403
   PubMed Web of Science ®Google Scholar
• RosendorffCDubielRXuJChavanuKJComparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophyAm J Cardiol200910435936519616668
   PubMed Web of Science ®Google Scholar
• ChobanianAVThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA20032892560257212748199
   PubMed Web of Science ®Google Scholar
• K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney diseaseAm J Kidney Dis2004431113
   PubMed Web of Science ®Google Scholar
• Summary of Revisions for the 2007 Clinical Practice RecommendationsDiabetes Care200730S3
   PubMed Web of Science ®Google Scholar